Lomitapide modifies high-density lipoprotein function in homozygous familial hypercholesterolaemia
Lomitapide modifies high-density lipoprotein function in homozygous familial hypercholesterolaemia
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Lomitapide reduces plasma low-density lipoprotein cholesterol (LDL-C) and is approved for the treatment of homozygous familial hypercholesterolemia (HoFH). This study aims to determine the effect of lomitapide on HDL and cholesterol efflux in a cohort of patients with HoFH.
Analysis included plasma samples from 17 HoFH patients enrolled in the l...
Alternative Titles
Full title
Lomitapide modifies high-density lipoprotein function in homozygous familial hypercholesterolaemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_cc467f83de66482ea1e832f4391954d7
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cc467f83de66482ea1e832f4391954d7
Other Identifiers
ISSN
2047-783X,0949-2321
E-ISSN
2047-783X
DOI
10.1186/s40001-025-02439-0
